• Earlier in June 2026, BeOne Medicines reported extensive new data at the European Hematology Association Congress showing BRUKINSA, tacabrutideg and BEQALZI delivering durable responses and favorable safety profiles across multiple B‑cell malignancies, alongside long-term outcomes in very elderly CLL/SLL patients and large real‑world datasets supporting BRUKINSA’s clinical performance.
• The breadth of late-stage and real-world evidence, combined with regulatory designations such as FDA Fast Track and EMA PRIME for tacabrutideg, underlines how BeOne is building an integrated hematology franchise that spans first‑line therapy, resistant disease and fixed‑duration oral combinations.
• We’ll now examine how tacabrutideg’s promising results in BTK inhibitor–resistant CLL/SLL may influence BeOne Medicines’ existing investment narrative.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

BeOne Medicines Investment Narrative Recap

To own BeOne Medicines, you need to believe its hematology franchise can justify current expectations despite heavy reliance on BRUKINSA and intense BTK competition. The new EHA data strengthen the near term catalyst around tacabrutideg’s Phase 3 program in BTK inhibitor resistant CLL/SLL, while the biggest risk remains single product concentration in CLL, where any clinical or competitive setback could quickly affect revenue and sentiment. Overall, the June data look supportive rather than thesis changing.

The most relevant recent announcement here is the large Phase 3 SEQUOIA update in very elderly CLL/SLL patients, plus real world datasets across more than 250,000 patients. Together with the new tacabrutideg and BEQALZI combination data, this breadth of evidence matters for the catalyst of reinforcing BRUKINSA as the preferred BTK backbone, even as investors weigh ongoing risks around pricing pressure and future rivals in the CLL segment.

Yet beneath the strong hematology story, investors should still be aware that...

BeOne Medicines' narrative projects $8.6 billion revenue and $1.6 billion earnings by 2029. This requires 14.3% yearly revenue growth and an earnings increase of about $1.1 billion from $513.0 million today.

Uncover how BeOne Medicines' forecasts yield a $411.51 fair value, a 56% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already cautious, assuming revenue growth of about 9.8% a year and earnings around US$985 million by 2029, so you should expect those more pessimistic voices to reassess both the upside from strong BTK data and the downside from BRUKINSA dependence in light of this new information.

Explore 5 other fair value estimates on BeOne Medicines - why the stock might be worth over 3x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your BeOne Medicines research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free BeOne Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BeOne Medicines' overall financial health at a glance.

Searching For A Fresh Perspective?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.